Dr. Ming Y. Lim, MB BCHIR
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 19
- In the NPI registry since
- 2009
- Medicare patients seen, 2024
- 69
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2009Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
UT license 10882813-1205 · SC license 37931 -
Hematology (Internal Medicine) Physician
SC license 37931 -
Internal Medicine Physician
MN license 54181 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Utah Hospital and Clinics Salt Lake City, UT
Medical groups
- University of Utah Adult Services (1,788 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 69
- Services billed
- 125
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 26 | 22 |
| New patient office or other outpatient visit, 60-74 minutes | 15 | 15 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 14 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Eliquis (apixaban) Other prescribers in Charleston, SC | 32 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 18 payments worth $25,338 in total to this clinician.
| E.r. Squibb & Sons, L.l.c. | $11,678 |
|---|---|
| Genzyme Corporation | $8,406 |
| Hema Biologics, LLC | $5,253 |
| Consulting Fee | $18,005 |
|---|---|
| Honoraria | $4,900 |
| Travel and Lodging | $1,943 |
| Food and Beverage | $490 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| E.r. Squibb & Sons, L.l.c. Oct 27, 2025 | Consulting Fee | $10,505 |
| Genzyme Corporation Nov 7, 2025 | Consulting Fee QFITLIA | $7,500 |
| Hema Biologics, LLC Mar 12, 2025 | Honoraria SEVENFACT · HEMATOLOGY | $4,900 |
| E.r. Squibb & Sons, L.l.c. Oct 4, 2025 | Travel and Lodging travel to Anaheim, CA | $808 |
| Genzyme Corporation Nov 7, 2025 | Travel and Lodging QFITLIA · travel to Dallas, TX · in-kind | $363 |
| Genzyme Corporation Nov 7, 2025 | Travel and Lodging QFITLIA · travel to Dallas, TX · in-kind | $297 |
| Genzyme Corporation Nov 7, 2025 | Travel and Lodging QFITLIA · travel to Dallas, TX · in-kind | $246 |
| E.r. Squibb & Sons, L.l.c. Oct 4, 2025 | Travel and Lodging travel to Anaheim, CA | $201 |
| Hema Biologics, LLC Mar 7, 2025 | Travel and Lodging SEVENFACT · HEMATOLOGY · travel to SAN DIEGO, CA · in-kind | $14.13 |
| Hema Biologics, LLC Mar 7, 2025 | Travel and Lodging SEVENFACT · HEMATOLOGY · travel to SAN DIEGO, CA · in-kind | $14.13 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $22,729 in research payments for these studies, mostly to the institutions running them.
- Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura
Genzyme Corporation · Completed · NCT05468320 - A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia
Genzyme Corporation · Active, not recruiting · NCT05662319
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.